DK0690675T5 - Nukleinsyre, der koder for en tumorafstödningsantigenprecursor - Google Patents

Nukleinsyre, der koder for en tumorafstödningsantigenprecursor

Info

Publication number
DK0690675T5
DK0690675T5 DK94911498T DK94911498T DK0690675T5 DK 0690675 T5 DK0690675 T5 DK 0690675T5 DK 94911498 T DK94911498 T DK 94911498T DK 94911498 T DK94911498 T DK 94911498T DK 0690675 T5 DK0690675 T5 DK 0690675T5
Authority
DK
Denmark
Prior art keywords
tumor rejection
rejection antigen
nucleic acid
antigen precursor
acid encoding
Prior art date
Application number
DK94911498T
Other languages
English (en)
Other versions
DK0690675T3 (da
Inventor
Vincent Brichard
Pel Aline Van
Thomas Wolfel
Thierry Boon-Falleur
Plaen Etienne De
Catia Traversari
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Publication of DK0690675T3 publication Critical patent/DK0690675T3/da
Application granted granted Critical
Publication of DK0690675T5 publication Critical patent/DK0690675T5/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK94911498T 1993-03-18 1994-03-09 Nukleinsyre, der koder for en tumorafstödningsantigenprecursor DK0690675T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/032,978 US5620886A (en) 1993-03-18 1993-03-18 Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
PCT/US1994/002487 WO1994021126A1 (en) 1993-03-18 1994-03-09 Nucleic acid coding for a tumor rejection antigen precursor

Publications (2)

Publication Number Publication Date
DK0690675T3 DK0690675T3 (da) 2004-06-01
DK0690675T5 true DK0690675T5 (da) 2008-11-17

Family

ID=21867896

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94911498T DK0690675T5 (da) 1993-03-18 1994-03-09 Nukleinsyre, der koder for en tumorafstödningsantigenprecursor

Country Status (17)

Country Link
US (2) US5620886A (da)
EP (1) EP0690675B1 (da)
JP (1) JP3433322B2 (da)
CN (1) CN1072719C (da)
AT (1) ATE258379T1 (da)
AU (1) AU675707B2 (da)
CA (1) CA2158446C (da)
DE (2) DE69433518T4 (da)
DK (1) DK0690675T5 (da)
ES (1) ES2210252T3 (da)
FI (1) FI954360A0 (da)
NO (1) NO953601L (da)
NZ (1) NZ263348A (da)
PT (1) PT690675E (da)
TW (1) TW442568B (da)
WO (1) WO1994021126A1 (da)
ZA (1) ZA941812B (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856091A (en) * 1993-03-18 1999-01-05 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
WO1995029193A2 (en) * 1994-04-22 1995-11-02 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services Melanoma antigens
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US5997870A (en) * 1994-06-03 1999-12-07 Ludwig Institute For Cancer Research Isolated peptides which bind to HLA-B44 Molecules
US5821122A (en) * 1995-06-07 1998-10-13 Inserm (Institute Nat'l De La Sante Et De La Recherche . .) Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US6096313A (en) * 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
FR2746110B1 (fr) * 1996-03-14 1998-04-17 Methode de traitement par therapie genique des tumeurs humaines et virus recombinants correspondants
US5674749A (en) * 1996-03-26 1997-10-07 Ludwig Institute For Cancer Research Monoclonal antibodies which bind to tumor rejection antigen precursor melan-A, and uses thereof
NZ333149A (en) * 1996-06-25 2000-06-23 Ludwig Inst Cancer Res Brain glycogen phosphorylase tumour rejection antigen precursors including antibodies to and nucleic acids coding them also methods and products for diagnosing and treating conditions characterised by expression of a BGPTR antigen or precursor thereof
DK0970206T3 (da) 1997-01-27 2008-10-13 Ludwig Inst Cancer Res Lage-1-tumorassocierede nukleinsyrer
US5879892A (en) * 1997-04-25 1999-03-09 Ludwig Institute For Cancer Research Leukemia associated genes
AU761256B2 (en) * 1998-01-26 2003-05-29 Genzyme Corporation Antigen-specific cells, methods of generating these cells and uses thereof
US7001999B1 (en) * 1998-04-15 2006-02-21 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
US6245525B1 (en) * 1998-07-27 2001-06-12 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
US6770456B1 (en) 1998-07-29 2004-08-03 Ludwig Institute For Cancer Research Endogenous retrovirus tumor associated nucleic acids and antigens
DE19913707A1 (de) * 1999-03-26 2000-10-05 Privates Inst Bioserv Gmbh Immunadsorber zur Sepsistherapie
CN1402782A (zh) 1999-10-19 2003-03-12 路德维哥癌症研究院 Mage-a12抗原肽及其应用
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
EP4091631A1 (en) 2002-01-30 2022-11-23 The Brigham and Women's Hospital, Inc. A tim-3 binding molecule for use in the treatment of a disease
US7311914B2 (en) * 2002-08-13 2007-12-25 Ludwig Institute For Cancer Research MAGE-A4 antigenic peptides and uses thereof
US7178491B2 (en) * 2003-06-05 2007-02-20 Caterpillar Inc Control system and method for engine valve actuator
AU2005265182B2 (en) * 2004-06-17 2012-06-21 Mannkind Corporation Epitope analogs
US20060159689A1 (en) * 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US20060008468A1 (en) * 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
AU2005326758B2 (en) 2004-06-23 2011-07-14 Board Of Regents Of The University Of Texas System Methods and compositions for the detection of biological molecules using a two particle complex
AU2005321898B2 (en) * 2004-12-29 2012-07-19 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
KR20080026181A (ko) 2005-06-17 2008-03-24 맨카인드 코포레이션 암세포 및 종양 기질에 발현된 우성 및 준우성 에피토프에대한 다가 면역반응을 유발하기 위한 방법 및 조성물
AU2006259307B2 (en) 2005-06-17 2012-12-20 Mannkind Corporation Epitope analogues
JP2008543869A (ja) 2005-06-17 2008-12-04 マンカインド コーポレイション 癌腫のための多価同調・増幅免疫療法
US8088379B2 (en) 2006-09-26 2012-01-03 The United States Of America As Represented By The Department Of Health And Human Services Modified T cell receptors and related materials and methods
WO2008148068A1 (en) * 2007-05-23 2008-12-04 Mannkind Corporation Multicistronic vectors and methods for their design
EA026990B1 (ru) 2007-11-07 2017-06-30 Селлдекс Терапьютикс Инк. Антитела, связывающиеся с человеческой клеткой dec-205
EP2490713A2 (en) 2009-10-23 2012-08-29 MannKind Corporation Cancer immunotherapy and method of treatment
CA2796571C (en) 2010-04-13 2019-10-29 Celldex Therapeutics Inc. Antibodies that bind human cd27 and uses thereof
HUE047385T2 (hu) 2014-06-06 2020-04-28 Bristol Myers Squibb Co Antitestek glükokortikoid indukált tumornekrózis faktor receptor (GITR) ellen és annak felhasználásai
US20180044429A1 (en) 2015-03-09 2018-02-15 Celldex Therapeutics, Inc. Cd27 agonists
WO2016196228A1 (en) 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Antibodies against ox40 and uses thereof
WO2017087678A2 (en) 2015-11-19 2017-05-26 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
WO2017184619A2 (en) 2016-04-18 2017-10-26 Celldex Therapeutics, Inc. Agonistic antibodies that bind human cd40 and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US5487974A (en) * 1992-12-22 1996-01-30 Ludwig Institute For Cancer-Research Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells

Also Published As

Publication number Publication date
CN1072719C (zh) 2001-10-10
ZA941812B (en) 1994-10-13
EP0690675B1 (en) 2004-01-28
US5854203A (en) 1998-12-29
JPH08507693A (ja) 1996-08-20
CA2158446C (en) 2009-01-06
EP0690675A4 (en) 1998-12-23
FI954360A (fi) 1995-09-15
NO953601L (no) 1995-10-31
ATE258379T1 (de) 2004-02-15
DE69433518D1 (de) 2004-03-04
US5620886A (en) 1997-04-15
WO1994021126A1 (en) 1994-09-29
CA2158446A1 (en) 1994-09-29
JP3433322B2 (ja) 2003-08-04
TW442568B (en) 2001-06-23
DE69433518T4 (de) 2009-07-23
ES2210252T3 (es) 2004-07-01
NZ263348A (en) 1996-06-25
AU6399394A (en) 1994-10-11
FI954360A0 (fi) 1995-09-15
DE69433518T2 (de) 2004-06-24
PT690675E (pt) 2004-06-30
EP0690675A1 (en) 1996-01-10
DK0690675T3 (da) 2004-06-01
AU675707B2 (en) 1997-02-13
NO953601D0 (no) 1995-09-13
CN1093406A (zh) 1994-10-12

Similar Documents

Publication Publication Date Title
DK0690675T5 (da) Nukleinsyre, der koder for en tumorafstödningsantigenprecursor
EA200200565A1 (ru) Применение клеток, трансфицированных днк, кодирующей лиганд мнс класса ii, и способ получения таких клеток
NO955063L (no) Isolerte peptider som danner komplekser av MHC-molekylet HLA-C-klon 10, samt anvendelse derav
NO960158D0 (no) Fremgangsmåte til diagnostisering av en lidelse ved å bestemme ekspresjon av GAGE-tumor-rejeksjonsantigenforlöpere
DK0845032T3 (da) Isolerede nucleinsyremolekyler, peptider, der danner komplekser med MHC-molekyler HLA-A2, samt anvendelser
HUP9801608A2 (hu) A 11. típusú humán papillomavírusból származó L1-fehérjét kódoló szintetikus HPV6/11-L1-hibrid-DNS
DE69008326D1 (de) Mehrstufenverfahren zur Herstellung von Hexafluoropropylen.
NO970030L (no) Isolert nukleinsyresekvens som koder for et tumor-rejeksjonsantigen presentert av HLA-A2
ES2192602T3 (es) Molecula de acido nucleico aislada y truncada, que codifica el antigeno de rechazo tumurall gage.
DE69022491T2 (de) Herstellung von Tertiär-Kohlenwasserstoff-Silyl-Verbindungen.
FR2575466B1 (fr) Nouveaux complexes de silicium hexacoordines, leur procede de preparation et leur application
DE3767493D1 (de) Wanderschichtreaktor zur entfernung von unerwuenschten, gasfoermigen bestandteilen aus gasen.
DE69008382T2 (de) Verfahren zur Herstellung von Organosiliziumverbindungen.
ATE265418T1 (de) Neue substituierte 3-phenoxy- und 3- phenylalkyloxy-2-phenyl-propylamine
DE3780665D1 (de) Mehrstufiges reduktionsverfahren zur herstellung von ferromagnetischem chromdioxid.
TW372973B (en) Isolated, truncated nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof
EA200000705A1 (ru) Промежуточные соединения и способ синтеза 17-замещенных 16.бета.-арилокси 4-азастероидов
ATE108832T1 (de) Verwendung von monoklonalen antikörpern gegen b2- mikroglobulin.
IT1180220B (it) Miscela di composti diastereoisomeri, ottenuti da (-)-5-(1-idrossi-1-metiletil)-2-metil-2-cicloesen-1-one, avente attivita' mucosecretolitica, procedimento per la sua preparazione e composizioni farmaceutiche che la contengono
ATE15486T1 (de) Verfahren zur herstelling von threo-3-(3,4dihydroxyphenyl)serin.
IT8025322A0 (it) Procedimento per la realizzazione di calzature, nonche' calzatura realizzata.
ATE55257T1 (de) Verfahren zur herstellung von hochgereinigten, hepatitis-b-virus-infektionsfreien gammaglobulinen.
IT8620610A0 (it) Procedimento per la fabbricazione di laterizi contenenti fanghi conciari.